Skip to nav Skip to content

Clinical Trial Search

294 Clinical Trials Found

Clinical Trial 23090

Disease Site: Lung
PI: Pellini, Bruna

Clinical Trial 23101

Disease Site: Other Hematopoietic
PI: Fernandez, Hugo

Clinical Trial 21262

A First in Human dose escalation of Dendritic Cell Vaccine (DCV) administered Intrathecally (IT) primed against HER2/HER3 in Patients with Leptomeningeal Disease (LMD) from Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Disease Site: Brain and Nervous System
PI: Forsyth, Peter

Clinical Trial 19722

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment
Disease Site: Multiple Myeloma
PI: Alsina, Melissa

Clinical Trial 90016

Disease Site: Other Hematopoietic
PI: Sandoval-Sus, Jose

Clinical Trial 21673

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety ofHER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-Based Therapy (FLAMINGO-01)
Disease Site: Breast
PI: Soyano Muller, Aixa

Clinical Trial 21676

Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan with Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer with Brain Metastases
Disease Site: Breast
PI: Ahmed, Kamran

Clinical Trial 17268-B

I-SPY 2.2 TRIAL - Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2
Disease Site: Breast
PI: Han, Heather

Clinical Trial 22196

A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects with Extensive Stage Small Cell Lung Cancer
Disease Site: Lung
PI: Chiappori, Alberto

Clinical Trial 22306

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
Disease Site: Any Site
PI: Eroglu, Zeynep

Clinical Trial 22333

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia
PI: Komrokji, Rami

Clinical Trial 22461

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies
Disease Site: Leukemia, other, Lymphoid Leukemia, Myeloid and Monocytic Leukemia
PI: Nishihori, Taiga